Search Results
Sep 09, 2026, 08:00 ET UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA®(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation Treatment of adults with moderate-to-severe plaque psoriasis (PSO) who are candidates for systemic therapy or phototherapyImportant Safety Information Serious and sometimes
More news about: UCB
Sep 03, 2026, 16:35 ET Renowned Systems Safety Expert Professor Najmedin Meshkati, PhD, Appointed to ECRI Board of Trustees
Practice Center by the U.S. Agency for Healthcare Research and Quality. The ECRI and Institute for Safe Medication Practices PSO is a federally certified Patient Safety Organization (PSO) as designated by the U.S. Department of Health and Human Services. ECRI is the only organization worldwide to conduct independent
More news about: ECRI
Aug 31, 2026, 07:00 ET New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
medication.Detailed 52-week results from TOGETHER-PsO and TOGETHER-PsA will be presented at future medical meetings and published in peer-reviewed journals.About the TOGETHER-PsO and TOGETHER-PsA TrialsTOGETHER-PsO (NCT06588283) and TOGETHER-PsA (NCT06588296) are 52-week
More news about: Eli Lilly and Company
Aug 25, 2026, 12:55 ET ECRI Expands Problem Reporting Network and Calls for More Data on AI Errors in Patient Care
Practice Center by the U.S. Agency for Healthcare Research and Quality. The ECRI and Institute for Safe Medication Practices PSO is a federally certified Patient Safety Organization (PSO) as designated by the U.S. Department of Health and Human Services. ECRI is the only organization worldwide to conduct independent
More news about: ECRI
Jul 29, 2026, 09:35 ET ECRI Names Cottage Health Winner of 2026 Health Technology Excellence Award
Practice Center by the U.S. Agency for Healthcare Research and Quality. The ECRI and Institute for Safe Medication Practices PSO is a federally certified Patient Safety Organization (PSO) as designated by the U.S. Department of Health and Human Services. ECRI acquired The Institute for Safe Medication Practices
More news about: ECRI
May 28, 2026, 19:10 ET FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
macrophages, and dendritic cells that is known to be a driver of immune-mediated diseases including active PsA, moderate to severe plaque psoriasis (PsO), moderate to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD). Findings are based on in vitro.5,6,7,8,9Editor's
More news about: Johnson & Johnson
May 26, 2026, 13:28 ET Data analysis by ECRI on patient falls reveals common risk factors
Practice Center by the U.S. Agency for Healthcare Research and Quality. The ECRI and Institute for Safe Medication Practices PSO is a federally certified Patient Safety Organization (PSO) as designated by the U.S. Department of Health and Human Services. ECRI acquired The Institute for Safe Medication Practices
More news about: ECRI
Apr 26, 2026, 14:01 ET Greater San Diego Science and Engineering Fair Students Win Big at the 75th California Science and Engineering Fair
Konda, Grade 11, Del Norte High School, Saban Family Foundation Scholar Prize, "Adaptive Swarm Coordination for Wildfire Control via Q-Learning Tuned PSO with Quantum-Inspired Coupling".Emma Liu, Grade 11, The Bishop's School, ISEF Finalist, 1st Place, "Defining 3D Phenotypic Cell States
More news about: Greater San Diego Science and Engineering Fair
Apr 20, 2026, 08:05 ET Accord BioPharma's IMULDOSA® (ustekinumab-srlf) Now Preferred Under Cigna Healthcare Commercial Plans
interleukin-12 and -23 antagonist indicated for the treatment of:Adult patients with:moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapyactive psoriatic arthritis (PsA)moderately to severely active Crohn's disease
More news about: Accord BioPharma
Apr 02, 2026, 07:00 ET JumpModel and Gogh Solutions Combine to Form a Leading Independent IFS Services Platform backed by Superstep Capital
complementary strengths across IFS ERP, IFS Cloud, Field Service Management (FSM), Enterprise Asset Management (EAM), Planning, Scheduling, and Optimization (PSO), and long-term managed services. Together, JumpModel and Gogh form one of the most comprehensive independent IFS-focused services partners in North
More news about: Superstep Capital
Mar 28, 2026, 10:00 ET ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ (icotrokinra) in the treatment of patients with moderate-to-severe plaque psoriasis (PsO). ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026
More news about: Johnson & Johnson
Mar 27, 2026, 09:00 ET UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
March 27, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new data in moderate-to-severe plaque psoriasis (PSO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, March 27–31. These data assess BIMZELX® (bimekizumab-bkzx) in
More news about: UCB
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
molecules and advancing novel science that uncovers the potential of incretins. Lilly recently shared topline findings from the TOGETHER-PsA and TOGETHER-PsO trials investigating the concomitant use of ixekizumab and an incretin-based therapy to treat adults with psoriatic disease and obesity or overweight
More news about: Eli Lilly and Company
Mar 18, 2026, 07:49 ET FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
the ICONIC clinical development program, which simultaneously evaluated ICOTYDE in adults and adolescents, high impact sites such as scalp and genital PsO, and in duplicate head-to-head trials versus an active comparator. In the head-to-head superiority studies, approximately 70% of patients achieved clear
More news about: Johnson & Johnson
Mar 16, 2026, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
expansion of small molecules and advancing novel science that uncovers the potential of incretins. Lilly recently shared topline findings from the TOGETHER-PsO and TOGETHER-PsA trials investigating the efficacy and safety of treating adults with psoriatic disease and obesity with both ixekizumab and an incretin-based
More news about: Eli Lilly and Company
Mar 11, 2026, 07:00 ET BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
psoriasis, psoriatic arthritis, axial spondyloarthritis (axSpA) and hidradenitis suppurativa, respectively) and oral candidiasis (7.3%, 2.3%, 3.7%, 5.6% in PSO, PsA, axSpA and HS, respectively). Common adverse reactions (≥1/100 to <1/10) were oral candidiasis, tinea infections, ear infections, herpes simplex
More news about: UCB
Mar 09, 2026, 10:51 ET AI use in diagnostic care, rural care access, and surge in preventable diseases top annual report of patient safety concerns
Practice Center by the U.S. Agency for Healthcare Research and Quality. The ECRI and Institute for Safe Medication Practices PSO is a federally certified Patient Safety Organization (PSO) as designated by the U.S. Department of Health and Human Services. ECRI acquired The Institute for Safe Medication Practices
More news about: ECRI
Feb 20, 2026, 08:02 ET Orrum Announces Strategic Partnership with LivaNova to Unite Intelligent Data with Innovative Perfusion Technology
pre- and post-operative analytics across the full patient care continuum.Built within a secure, legally privileged Patient Safety Organization (PSO) recognized by the U.S. Department of Health & Human Services, Orrum's platform integrates curated advanced data visualizations, powerful analytics,
More news about: Orrum Clinical Analytics
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
agonist obesity management medication.Detailed 36-week results from TOGETHER-PsO will be published in a peer-reviewed journal and discussed with regulators.About the TOGETHER-PsO TrialTOGETHER-PsO (
More news about: Eli Lilly and Company
Feb 12, 2026, 06:57 ET AEP Reports Fourth Quarter and Full-Year 2025 Results, Reaffirms Long-Term Growth Outlook
Represents the impact of receiving IRS PLRs related to NOLCs in retail ratemaking on I&M, PSO and SWEPCo. Amount includes a reduction in Excess ADIT and activity related to prior periods
More news about: American Electric Power
Feb 05, 2026, 15:33 ET Fragmented Data Strategies Are Undermining Margins at Professional Service Organizations, Warns Info-Tech Research Group
into executive-ready artifacts, clear ownership, and next steps for implementationThe blueprint also includes supporting tools, such as PSO-specific interview guides, data value mapping templates, and executive presentation materials, to help firms secure alignment and sponsorship at the
More news about: Info-Tech Research Group
Jan 21, 2026, 11:21 ET Misuse of AI chatbots tops annual list of health technology hazards
Practice Center by the U.S. Agency for Healthcare Research and Quality. The ECRI and Institute for Safe Medication Practices PSO is a federally certified Patient Safety Organization (PSO) as designated by the U.S. Department of Health and Human Services. ECRI acquired The Institute for Safe Medication Practices
More news about: ECRI
Jan 08, 2026, 14:00 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
from the TOGETHER-PsA trial will be presented at an upcoming medical meeting and discussed with regulators. Topline results from the ongoing TOGETHER-PsO trial, investigating the efficacy and safety of treating adults who have moderate-to-severe plaque psoriasis and obesity or overweight with concomitant
More news about: Eli Lilly and Company
Dec 02, 2025, 08:05 ET Carta Healthcare Partners with Fivos to Elevate Data Quality and Advance Vascular Patient Care
Society for Vascular Surgery® Vascular Quality Initiative® (SVS VQI) is governed by the SVS Patient Safety Organization (SVS PSO), a wholly owned subsidiary of the Society for Vascular Surgery, which provides oversight of data sharing arrangements, key outcome and quality measure
More news about: Carta Healthcare
Dec 01, 2025, 08:05 ET Accord BioPharma's IMULDOSA® (ustekinumab-srlf) Added to Express Scripts National Commercial Formularies
interleukin-12 and -23 antagonist indicated for the treatment of:Adult patients with:moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapyactive psoriatic arthritis (PsA)moderately to severely active Crohn's disease
More news about: Accord BioPharma